Company intelligence / Profile preview

Bluejay Diagnostics, Inc.

Acton, Massachusetts, United Statesbluejaydx.com ↗

Ownership: Public · BJDX
Employees: ~10
Development stage: Preclinical

Overview

The SYMON-I pilot study showed promising results for IL-6 as a biomarker to prognosticate mortality and predict microbiological culture positivity in sepsis patients. The company has advanced to the SYMON-II validation study with active enrollment underway. Recent abstract acceptance for presentation at the 2025 SAEM Annual Meeting indicates continued clinical progress for their Symphony IL-6 Test in sepsis management[7].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Diagnostic testsBiomarker detection
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

Symphony IL-6 Test

Pre-clinical

Indications: Sepsis

Financials

Market cap: $1M
Total revenue: $0
Enterprise value: $-8.5M

Beyond the preview

Go deeper on Bluejay Diagnostics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bluejay Diagnostics, Inc..

Explore the full profile